Filing Flows › Health Care › Aktis Oncology (AKTS)
Aktis Oncology (AKTS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Aktis Oncology (AKTS) Q2 2026 earnings results →
Q2 2026 Revenue up 111% year over year to $3.4M · 713¢ of every $1 of revenue lost · operating margin -854.0%
Aktis Oncology made $3.4M in Q2 2026 (+111% Y/Y). Operating margin -854.0%, net loss $24.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.4M in Q2 2026, up 111% year over year and up 5% from the previous quarter.
Operating costs exceeded revenue by $28.9M, an operating margin of -854.0%. Total costs grew 43% against revenue growth of 111%. The fastest-growing cost line was General & admin (+78%). The quarter ended with a net loss of $24.1M, wider than the previous quarter's $18.3M loss.
Operating cash flow was −$20.6M. Non-cash charges added back $879K of depreciation and amortization and $3.2M of share-based compensation. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$21.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $3.4M | +111% | -854.0% | −$24.1M | −$20.6M |
| Q1 2026 | 10-Q | May 11, 2026 | $3.2M | +123% | -703.6% | −$18.3M | −$24.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Aktis Oncology
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anticancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end clinical supply chain built for resiliency and scalability, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.
In its own words, from its 8-K, filed Aug 13, 2026.
Aktis Oncology against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +111% against the peers' median +10%. Operating margin: -854.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AKTS Aktis Oncology | Q2 2026 | $3.4M | +111% | -854.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Aktis Oncology 10-Q on SEC EDGAR · CIK 2035832 · Pharmaceutical Preparations
13F: who owns AKTS and who is buying
More on AKTS
History
Every quarter: Q2 2026 results · Q1 2026 results